American Nutrition Association Announces Initiative with Jazz Pharmaceuticals to Advance Evidence-Based Sodium Reduction and Cardiovascular Health Education

(High)

(Positive)

Rhea-AI Summary

American Nutrition Association and Jazz Pharmaceuticals (NYSE:JAZZ) announced a collaboration on March 24, 2026 to advance evidence-based sodium reduction education for people with narcolepsy and idiopathic hypersomnia. The initiative emphasizes sodium’s role in blood pressure and cardiovascular risk, cites average U.S. intake (~3,400 mg/day) versus recommended 1,500–2,300 mg, and notes CVD causes ~700,000 U.S. deaths annually. The program will produce patient and clinician resources to identify sodium exposures (food, beverages, medications) and encourage actionable sodium-reduction strategies for at-risk sleep-disorder populations.

News Market Reaction – JAZZ

+1.48%

+1.48% Session close to close

In the Mar 24 session, JAZZ gained 1.48%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

Market Context

This announcement highlights Jazz’s collaboration with the American Nutrition Association to deliver...

Analysis

This announcement highlights Jazz’s collaboration with the American Nutrition Association to deliver evidence-based nutrition education for people with narcolepsy or idiopathic hypersomnia, who face elevated cardiovascular and cardiometabolic risk. It emphasizes total sodium exposure, with recommended intake of 1,500–2,300 mg per day versus an average 3,400 mg. In the broader context of recent oncology data and strong 2025 financial results, this initiative underscores Jazz’s focus on comprehensive care beyond medicines alone.

Key Figures

Annual CVD deaths: 700,000 deaths per year Average sodium intake: 3,400 mg per day Recommended sodium intake: 1,500–2,300 mg per day +1 more

4 metrics

Annual CVD deaths 700,000 deaths per year Cardiovascular disease mortality in the United States

Average sodium intake 3,400 mg per day Average daily sodium consumption for Americans

Recommended sodium intake 1,500–2,300 mg per day Total daily recommended sodium intake range

Excess intake above limit Nearly 50% above Average sodium intake vs recommended upper limit

Historical Context

4 past events · Latest: Mar 18 (Positive)

Pattern 4 events

Date	Event	Sentiment	24h Move	Catalyst
Mar 18	Oncology data update	Positive	-0.5%	Multiple oncology presentations, including 30% pCR in Phase 2 NeoZanHER.
Feb 24	Earnings and guidance	Positive	+13.2%	Record 2025 revenue, growth in key products, and 2026 guidance.
Feb 17	Investor conferences	Neutral	+0.4%	Participation in March healthcare investor conferences and webcasts.
Feb 10	Earnings date notice	Neutral	+0.4%	Announcement of timing for Q4 and full-year 2025 results call.

24h Move is the share-price change in the day after each event; other market factors may also have contributed.

Pattern Detected

Recent fundamentally positive news (notably earnings) often aligned with gains, while some positive clinical updates saw modest pullbacks.

Recent Company History

Over recent months, Jazz reported record 2025 revenue with a strong Q4, issued 2026 guidance, highlighted multiple oncology data sets, and maintained active investor outreach via conferences and scheduled earnings communications. The earnings release on Feb 24, 2026 coincided with a double‑digit gain, while the oncology data update on Mar 18, 2026 saw a small decline. Today’s education-focused collaboration with the American Nutrition Association fits Jazz’s strategy around sleep and cardiovascular comorbidities rather than a direct financial catalyst.

Key Terms

narcolepsy, idiopathic hypersomnia, cardiometabolic, hypertension, +3 more

7 terms

narcolepsy medical

"support people living with narcolepsy or idiopathic hypersomnia (IH) sleep disorders"

A chronic neurological condition that causes sudden, uncontrollable episodes of deep sleep and extreme daytime drowsiness, like a phone that unexpectedly shuts off during the day. It matters to investors because it defines the market need for treatments, influences clinical trial results and regulatory decisions, and can drive revenue or risk for companies developing medications, devices, or diagnostics tied to sleep disorders.

idiopathic hypersomnia medical

"people living with narcolepsy or idiopathic hypersomnia (IH) sleep disorders"

A chronic sleep disorder that causes extreme daytime sleepiness and prolonged, unrefreshing sleep despite adequate night sleep, with no identifiable medical or neurological cause. Think of it like a phone battery that won’t hold charge: sufferers remain tired and less productive even after long rest. For investors, idiopathic hypersomnia matters because it creates demand for treatments, diagnostics and supportive services, influencing market opportunities and regulatory pathways in sleep medicine.

cardiometabolic medical

"associated with elevated cardiovascular (CV) and cardiometabolic (CM) risk"

Cardiometabolic describes health conditions that affect the heart and the body’s metabolism—most commonly heart disease, high blood pressure, type 2 diabetes and obesity—that often occur together and share common causes. Investors care because these linked conditions drive large, predictable demand for drugs, medical devices and long-term care, and changes in treatment options, guidelines or costs can materially affect healthcare company revenues and government spending much like a problem in an engine and its fuel system impacts the whole vehicle.

hypertension medical

"modifiable risk factor for hypertension and cardiovascular disease (CVD)"

Hypertension is a condition where blood pressure in the arteries remains consistently high, making the heart work harder than normal to pump blood through the body. For investors, it can signal underlying health issues that might lead to increased medical costs or decreased productivity, potentially affecting a company's stability or the overall economy. Think of it as a warning sign of ongoing strain within a system that needs careful monitoring.

cardiovascular disease (CVD) medical

"modifiable risk factor for hypertension and cardiovascular disease (CVD), a leading cause"

A group of conditions that affect the heart and blood vessels, such as heart attacks, strokes and chronic artery problems; think of the body’s circulation as a pump-and-pipe system where blockages or pump failures harm performance. Investors care because cardiovascular disease drives demand for drugs, devices, insurance and medical services, influences productivity and healthcare costs, and can affect the valuation, revenues and regulatory risk of companies in healthcare and related industries.

over-the-counter financial

"including food, beverage, and prescription or Over-the-Counter medications"

Over-the-counter describes securities or trades that occur directly between buyers and sellers rather than on a formal stock exchange. Think of it like buying at a flea market instead of a big supermarket: prices, rules and transparency can vary, which can mean lower liquidity, wider price swings and less regulatory oversight—factors investors watch because they affect ease of trading and risk level.

comorbidities medical

"experience disproportionately higher prevalence of CV and CM comorbidities"

Comorbidities are other medical conditions a patient has alongside a primary illness, like extra weight in a car that makes the trip harder. For investors, they matter because additional illnesses can change how well treatments work, raise healthcare costs, affect insurance payouts and regulatory trial results, and therefore influence the market size, pricing, and risk for drugs, devices, and health services.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

03/24/2026 - 01:49 PM

Joint initiative aims to provide scientific validation for patient empowerment, clinician education on lower sodium intake and cardiovascular comorbidity awareness

CHICAGO, March 24, 2026 /PRNewswire/ -- The American Nutrition Association (ANA) today announced its initiative with Jazz Pharmaceuticals to provide evidence-based nutritional education to support people living with narcolepsy or idiopathic hypersomnia (IH) sleep disorders associated with elevated cardiovascular (CV) and cardiometabolic (CM) risk, which make targeted, proactive nutrition even more critical. Together, they aim to translate the latest nutrition science into actionable, patient-centered guidance for people living with these conditions, and empower them to feel confident, informed, and supported in their nutritional and health choices.

People living with narcolepsy or IH experience disproportionately higher prevalence of CV and CM comorbidities, even at younger ages than may be expected.¹^,² In these populations, sodium intake plays a clinically meaningful role in elevating blood pressure and increasing long-term CV risk, making proactive management of modifiable risk factors, such as sodium exposures from medications, important for this patient population.¹^,²

Excess dietary sodium, including food, beverage, and prescription or Over-the-Counter medications, is a modifiable risk factor for hypertension and cardiovascular disease (CVD), a leading cause of death in the United States, accounting for approximately 700,000 deaths each year.³ The average American consumes upwards of 3,400 mg of sodium each day, which is nearly 50% above the recommended upper limit.⁴ Despite decades of evidence supporting sodium reduction as a key strategy to lower CV risk, sodium remains widely underrecognized as a modifiable risk factor, and awareness and adherence to a total daily recommended intake of 1,500 to 2,300 mg sodium remains a challenge, especially for people living with narcolepsy or IH.¹^,²

"The American Nutrition Association is dedicated to advancing the science of nutrition and translating that science into meaningful action for patients and healthcare professionals alike," said Corinne Bush, MS, CNS, CEO of the American Nutrition Association. "At ANA, the first of our core values is that nutrition is a science. Excess sodium intake is one of the most meaningful and modifiable contributors to elevated blood pressure and CV risk, and through this partnership with Jazz Pharmaceuticals, we are putting that science to work for the patients who need it most."

Through this collaboration, people living with or at risk for CVD, including patients with narcolepsy or IH, will have access to credible, science-backed resources to understand the benefits and risks of total sodium exposure and empower patients to gain control of their health through the choices they make. Healthcare providers will be more equipped with peer-to-peer, evidence-based resources to have meaningful conversations with their patients about sodium reduction as a modifiable factor and a cornerstone of CV risk mitigation.⁵

"For decades, we have been committed to pioneering care for patients with serious and rare conditions, including narcolepsy and IH, and recognize that transforming patient outcomes requires more than medicines alone," said Sarah McMahon, Ph.D., senior vice president and sleep franchise head of Jazz Pharmaceuticals. "By partnering with the American Nutrition Association, we are merging scientific rigor and patient-centered education to empower people to make informed, healthier choices around the impact of total sodium intake and the need for actionable steps to reduce sodium exposure in people with inherent CV/CM risk."

Further details on programming and resources will be released as the collaboration progresses.

About the American Nutrition Association
The American Nutrition Association (ANA) is a nonprofit organization committed to advancing the science of personalized nutrition and translating that science into meaningful action for patients, healthcare professionals and communities. ANA brings together leading researchers, clinicians and nutrition scientists to build and disseminate evidence-based guidance that empowers people to make informed dietary choices and improve long-term health outcomes. Through education, advocacy and strategic partnerships, ANA works to bridge the gap between nutrition science and everyday practice. Please visit www.theana.org for more information.

About Jazz Pharmaceuticals
Jazz Pharmaceuticals plc (Nasdaq: JAZZ) is a global biopharma company whose purpose is to innovate to transform the lives of patients and their families. We are dedicated to developing life-changing medicines for people with rare disease — often with limited or no therapeutic options. We have a diverse portfolio of medicines, including leading therapies addressing epilepsies, cancers and sleep disorders. Our patient-focused and science-driven approach powers pioneering research and development advancements across our robust pipeline of innovative therapeutics. Jazz is headquartered in Dublin, Ireland with research and development laboratories, manufacturing facilities and employees in multiple countries committed to serving patients worldwide. Please visit www.jazzpharmaceuticals.com for more information.

ANA Media Contact:
Amy Smith, Senior Director of Nutrition Programs and Advocacy - American Nutrition Association - asmith@theana.org

References

¹ Saad R, Lillaney P, Profant DA, Fuller DS, Poole EM, Alvord T, Prince P, Desai S, Whalen M, Ni W, Black J. Cardiovascular burden of individuals diagnosed with idiopathic hypersomnia: Real-World Idiopathic Hypersomnia Total Health Model (CV-RHYTHM). Sleep Med. 2025 Sep;133:106587. doi: 10.1016/j.sleep.2025.106587. Epub 2025 May 19. PMID: 40494110.
² Thorpy MJ, et al. Cardiovascular Risks in People With Narcolepsy: Expert Panel Consensus Recommendations. Journal of the American Heart Association. 2025. https://www.ahajournals.org/doi/10.1161/JAHA.124.035168³ Centers for Disease Control and Prevention. Heart Disease Facts. https://www.cdc.gov/heartdisease/facts.htm. Accessed February 2026.
⁴ U.S. Food and Drug Administration. Sodium Reduction in the Food Supply. https://www.fda.gov/food/nutrition-food-labeling-and-critical-foods/sodium-reduction-food-supply . Accessed February 2026.
⁵ American Heart Association. Sodium and Salt. https://www.heart.org/en/healthy-living/healthy-eating/eat-smart/sodium/sodium-and-salt. Accessed February 2026.

View original content:https://www.prnewswire.com/news-releases/american-nutrition-association-announces-initiative-with-jazz-pharmaceuticals-to-advance-evidence-based-sodium-reduction-and-cardiovascular-health-education-302723801.html

SOURCE American Nutrition Association

FAQ

What is the American Nutrition Association and Jazz Pharmaceuticals partnership announced March 24, 2026 (JAZZ)?

It is a collaboration to develop evidence-based sodium reduction education for patients with narcolepsy or idiopathic hypersomnia. According to the company, the program will create patient and clinician resources addressing total sodium exposure from food, beverages, and medications to lower cardiovascular risk.

How does the initiative address sodium’s role in cardiovascular risk for people with narcolepsy or IH (JAZZ)?

The initiative focuses on translating nutrition science into actionable guidance to reduce sodium exposure and blood pressure. According to the company, it highlights sodium from diet and medications and equips clinicians with peer-to-peer resources for risk-mitigation conversations.

What baseline sodium and cardiovascular statistics are cited in the March 24, 2026 announcement (JAZZ)?

The announcement cites an average U.S. sodium intake of about 3,400 mg/day versus recommended 1,500–2,300 mg/day. According to the company, cardiovascular disease causes roughly 700,000 U.S. deaths annually, underscoring sodium reduction importance.

Will the American Nutrition Association and Jazz Pharmaceuticals release clinical or prescribing changes for JAZZ medications?

The announcement does not change prescribing or clinical indications for medications; it focuses on education and awareness. According to the company, forthcoming programming will provide resources on total sodium exposure rather than altering product labels or prescribing guidance.

When will resources from the ANA and Jazz Pharmaceuticals collaboration be available for patients and providers (JAZZ)?

The release states that further details and programming will be shared as the collaboration progresses, but gives no firm dates. According to the company, additional timing and resource availability will be announced in future updates.